Prescient Therapeutics Advances Lead Asset PTX-100 through Phase 2a Trials as Pharmaceutical Dealmaking Accelerates
Prescient advances PTX-100 in Phase 2a for CTCL; DOC review set for Dec 2026 as Prescient accelerates toward registration data amid booming pharma dealmaking.